Study Shows Benefits of GS-7977 in Treating Hepatitis C

50 %
50 %
Information about Study Shows Benefits of GS-7977 in Treating Hepatitis C
Health & Medicine

Published on March 10, 2014

Author: roberthindes

Source: slideshare.net

Description

Robert Hindes, MD, the cofounder and chief medical officer of BeyondWest Pharmaceuticals, has more than a decade of experience in the pharmaceutical industry. In 2012, Robert Hindes, MD, and other researchers presented an abstract describing the first successful use of daclatasvir (NS5A inhibitor) and sofosbuvir in a liver transplant recipient with recurrent cholestatic hepatitis C at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle.

By Robert Hindes MD

 Robert Hindes, MD, the cofounder and chief medical officer of BeyondWest Pharmaceuticals, has more than a decade of experience in the pharmaceutical industry. In 2012, Robert Hindes, MD, and other researchers presented an abstract describing the first successful use of daclatasvir (NS5A inhibitor) and sofosbuvir in a liver transplant recipient with recurrent cholestatic hepatitis C at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle.

 Formerly known as PSI-7977, sofosbuvir is a nucleotide analog, structurally similar to one of the molecules that make up the structural units of RNA. These can be modified to serve as antiviral drugs. The study showed that sofosbuvir, in combination with daclatasvir, successfully eradicated recurrent HCV in a post- transplant patient with cholestatic hepatitis. In more recent studies, treatment of previously untreated patients with sofosbuvir in combination with another NS5A inhibitor has resulted in high SVR rates after only 8 weeks of treatment.

Add a comment

Related presentations

Related pages

Hepatitis C - Treat or Wait? - Hepatitis C New Drug ...

Can Hepatitis C Be Cured? Hepatitis C - Treat or Wait ... the risks and benefits of treating the hepatitis C ... study shows that immediate ...
Read more

New 2011 AASLD guidelines for treating HCV - Hepatitis C ...

... and Treating Hepatitis C ... the potential benefits of erythropoietin must be ... therapy in chronic hepatitis C: a randomized study of treatment ...
Read more

2016 - Treating Hepatitis C - Hepatitis C New Drug ...

2016 - Treating Hepatitis C ... Treating Hepatitis C In ... ribavirin in patients with hepatitis C virus infection. “This study demonstrated ...
Read more

Hepatitis C News Ticker- GS-7977 + Ribavirin Pre ...

Hepatitis C News Ticker- GS-7977 + Ribavirin Pre-Transplant Open-Label Study. 0. ... Study shows how ... hepatitis C vi... Hepatitis C News Ticker- GS-7977 ...
Read more

HCV New Drug Research : Hepatitis C patients likely to ...

Hepatitis C patients likely to falter in adherence to treatment regimen over time, Penn study shows ... (GS-7977) Ledipasvir ...
Read more

Hepatitis C News - Hepatitis C Association

New Johns Hopkins study shows hepatitis C infection ... Clinical Benefits in Patient Subset ... Effective for Treating Chronic Hepatitis C?
Read more

HCV New Drug Research : Vitamin D Is Among The Best ...

... New Study Shows Connection Between Deficiency And Hepatitis B Virus ... GS-7977 sofosbuvir /GS-5885 ... Miravirsen-Treating hepatitis C by blocking a ...
Read more

The beginning of the end of hepatitis C? - Aidsmap

The beginning of the end of hepatitis C? ... who are experienced in treating both HIV and hepatitis C and who can ... a study shows that telaprevir ...
Read more

Hepatitis C Genotype 4 - Hepatitis C New Drug Research And ...

... (GS-7977), a uridine nucleotide ... Researchers can now study replication of Hepatitis C virus genotypes 3 and 4 in cultured cells, ... Study Shows The ...
Read more